DC
BBOT

Diametric Capital’s BridgeBio Oncology BBOT Stock Holding History

Diametric Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,280
Closed -$146K – 717
2026
Q1 		$146K Buy
+16,280
New +$175K 0.04% 402

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Diametric Capital's BBOT Position: Q2 2026 in Review

Diametric Capital sold out of BridgeBio Oncology (BBOT) in Q2 2026, closing a stake of 16,280 shares — an estimated $146K sold.

Diametric Capital first reported a position in BBOT in Q1 2026 and held it in 1 quarter. The position peaked at $146K in Q1 2026. 66 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Diametric Capital reported no remaining BridgeBio Oncology position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 16,280 BridgeBio Oncology shares in Q2 2026, an estimated $146K.
  • Diametric Capital first reported a position in BridgeBio Oncology in Q1 2026 and held it in 1 quarter.
  • Diametric Capital's BridgeBio Oncology position peaked at $146K in Q1 2026.
  • 66 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.